In 2019, an updated analysis from the Hereditary Breast and Ovarian Cancer Netherlands (HEBON) multicenter cohort reported an incidence of breast cancer in 0.7% of 1128 BRCA1/2 patients who underwent bilateral RRM compared to 23.8% of 1729 carriers who elected for surveillance during a median follow-up of 10 years [15]. The gene discussed is BRCA1; the disease is ovarian carcinoma.